Biological Properties of the Thromboplastins and Plasmas Included in the ICTH/ICSH Collaborative Study on Prothrombin Time Standardization

Summary

The fourteen types of thromboplastin included in the ICTH/ICSH Collaborative Study on Prothrombin Time Standardization were investigated with respect to their sensitivity for factor VII, activation products, and PIVKAs. All of these thromboplastins displayed sufficient factor VII sensitivity, and all were sensitive to activation products. After correction for the overall sensitivity slope, rabbit plain thromboplastins were the most sensitive preparations and human as well as rabbit diluted the least sensitive; bovine brain thromboplastin lost its exceptional position. Sensitivity to activation products explains why factors II, VII, and X present in artificially prepared abnormal plasmas may be difficult to assess accurately. Also, all thromboplastins appear to be sensitive for both PIVKA VII and PIVKA X. PIVKA VII acts as a procoagulant which increases the amount of factor VII measured by the one-stage assay technique. PIVKA X inhibits and thus reduces the activity of factor X. The procoagulant activity of PIVKA VII is particulary pronounced for the two lung-brain rabbit thromboplastins (Lyoplastin and Simplastin), whereas the anticoagulant action of PIVKA X is strongest with bovine brain thromboplastin (Thrombotest). Considered as a group, rabbit thromboplastins appear to be less sensitive for PIVKA X and more sensitive for PIVKA VII.

As judged from thromboplastin calibration results, all three types of lyophilized reference plasmas are to some degree distinguishable from fresh patient plasmas. Primary calibration of a thromboplastin must therefore still be performed with freshly prepared normal as well as patient plasmas.

• References

• 1 Averdunk R. 1971 Standardisierung und Korrelation von Gerinnungsanalysen. Habilitationsschrift. Institut für klinische Chemie und klinische Biochemie der freien Universität Berlin, Klinikum Steglitz
• 2 Bas BM, Müller AD, Voort-Beel JM Van Der. 1975; The relation between staphylocoagulase reacting factor and proteins induced by vitamin K antagonists. Journal of Molecular Medicine 1: 65
• 3 Borchgrevink CF, Pool JG, Stormorken H. 1960; A new assay for factor V (proaccelerin- accelerin) using Russell’s Viper Venom. Journal of Laboratory and Clinical Medicine 55: 625
• 4 Cleton FJ, Loeliger EA. 1960; Two typical hereditary charts of congenital factor VII deficiency. Thrombosis and Haemostasis (Stuttg.) 5: 87
• 5 Dam FE Van, Pauw BE De, Schutjes CP M, Veuger AJ L M. 1975; Isolated factor X deficiency in amyloidosis. Netherlands Journal of Medicine 18: 129
• 6 Duk-Wierda CA Van, Hermans J, Loeliger EA, Roos J. 1977; Interlaboratory oral anticoagulant quality assessment by the Netherlands Federation of Thrombosis Services. Thrombosis and Haemostasis 37: 509
• 7 Duckert F, Marbet GA. 1977; Die Kontrolle der oralen Antikoagulation - der therapeutische Bereich. Schweizerische Rundschau für Medizin (PRAXIS) 66 10: 293
• 8 Funvandraat LJ, Wermeskerken RK A Van. 1976; Family with factor V deficiency (parahaemophilia). Netherlands Journal of Medicine 19: 135
• 9 Hemker HC, Veltkamp JJ, Loeliger EA. 1968; Kinetic aspects of the interaction of blood clotting enzymes III. Demonstration of an inhibitor of prothrombin conversion in vitamin K deficiency. Thrombosis and Haemostasis (Stuttg.) 19: 346
• 10 Hemker HC, Müller AD, Loeliger EA. 1970; Two types of prothrombin in vitamin K deficiency. Thrombosis and Haemostasis (Stuttg.) 23: 633
• 11 Hemker HC, Swart AC W, Alink AJ M. 1972; Artificial reagents for factor VII and factor X, a computer programme for obtaining reference tables for one-stage determinations in the extrinsic system. Thrombosis and Haemostasis (Stuttg.) 27: 205
• 12 ICTH/ICSH. 1979; Prothrombin time standardization. Report of the Expert Panel on Oral Anticoagulant Control. The International Committee on Thrombosis and Haemostasis. The International Committee for Standardization in Haematology Thrombosis and Haemostasis 42: 1073
• 13 Kahan J, Norén I. 1975; Assessment of different mathematical models for calculating and expressing the results of coagulation test procedures. Thrombosis and Haemostasis (Stuttg.) 34: 522
• 14 Lenehan JG. 1977 Personal communication.
• 15 Loeliger EA, Roller F. 1952; Behaviour of factor VII and prothrombin during late pregnancy and in the newborn. Acta haematologica 7: 157
• 16 Loeliger EA. 1958; Schlechte Eigenschaft langwirkender Cumarine oder fiir deren Kontrolle ungeeignete Thrombokinase. Schweizerische medizinische Wochenschrift 88: 639
• 17 Loeliger EA, Hemker HC. 1970; Standardization in the laboratory control of oral anticoagulants. Thrombosis and Haemostasis (Stuttg.) Suppl 40: 359
• 18 Loeliger EA. 1973. Anticoagulant induced haemorrhages. In Girdwood RH. (ed) Blood disorders due to drugs and other agents. Excerpta Medica; Amsterdam: p 221
• 19 Loeliger EA, Halem-Visser LP Van. 1975; A simplified thromboplastin calibration procedure for standardization of anticoagulant control. Thrombosis and Haemostasis (Stuttg.) 33: 172
• 20 Miale JB, Kent JW. 1972; Standardization of the therapeutic range for oral anticoagulants based on standard reference plasmas. American Journal of Clinical Pathology 57: 80
• 21 Yoshitoshi Y, Naito C, Kikuchi A, Yamazaki S, Matsumura T, Yamanaka M. 1964; Statistical comparison of Thrombotest with Quick’s method. Tokushima Journal of Experimental Medicine 10: 245